NZ567982A - Influenza vaccines extemporaneously adsorbed to aluminium adjuvants - Google Patents

Influenza vaccines extemporaneously adsorbed to aluminium adjuvants

Info

Publication number
NZ567982A
NZ567982A NZ567982A NZ56798206A NZ567982A NZ 567982 A NZ567982 A NZ 567982A NZ 567982 A NZ567982 A NZ 567982A NZ 56798206 A NZ56798206 A NZ 56798206A NZ 567982 A NZ567982 A NZ 567982A
Authority
NZ
New Zealand
Prior art keywords
component
antigen
extemporaneously
adsorbed
adjuvant
Prior art date
Application number
NZ567982A
Inventor
Anthony Colegate
Philip Sizer
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Priority claimed from PCT/GB2006/004138 external-priority patent/WO2007052060A1/en
Publication of NZ567982A publication Critical patent/NZ567982A/en

Links

Abstract

Disclosed is a kit when used to prepare an immunogenic composition at the point of use or within 12 hours before use of said immunogenic composition, said kit comprising: (i) an antigen component, comprising an influenza virus antigen; and (ii) an adjuvant component, comprising an aluminium salt, wherein the antigen component and the adjuvant component are separate, and wherein the immunogenic composition is prepared by mixing of the antigen component and the adjuvant component at the point of use or within 12 hours before use. Also disclosed is a process for preparing an influenza vaccine, comprising the steps of: (i) preparing an antigen component comprising an influenza virus antigen; (ii) preparing an adjuvant component comprising an aluminium salt; and (iii) combining the antigen and adjuvant components at the point of use, or within 12 hours of use of said influenza vaccine.
NZ567982A 2005-11-04 2006-11-06 Influenza vaccines extemporaneously adsorbed to aluminium adjuvants NZ567982A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2260105A 2005-11-04 2005-11-04
US73560505P 2005-11-09 2005-11-09
PCT/GB2006/004138 WO2007052060A1 (en) 2005-11-04 2006-11-06 Influenza vaccines extemporaneously adsorbed to aluminium adjuvants

Publications (1)

Publication Number Publication Date
NZ567982A true NZ567982A (en) 2012-10-26

Family

ID=47042255

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ567982A NZ567982A (en) 2005-11-04 2006-11-06 Influenza vaccines extemporaneously adsorbed to aluminium adjuvants

Country Status (1)

Country Link
NZ (1) NZ567982A (en)

Similar Documents

Publication Publication Date Title
MX2010008468A (en) NUCLEIC ACIDS COMPRISING FORMULA (NuGlX<sub >mGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS.
WO2007052155A3 (en) Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
EA200801251A1 (en) VACCINES AGAINST FLU ADSORBED ON ALUMINUM ADJUVANTS FOR IMMEDIATE ADMISSION
PL1951299T3 (en) Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
MY150706A (en) Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
MXPA01007760A (en) Immunological adjuvant compound.
NZ592977A (en) IgE CH3 PEPTIDE VACCINE
CL2011003192A1 (en) (2s) -3- (2-fluoro-5- (5-fluoro-1h-pyrrolo [2,3-b] pyridin-3-yl) phenylamino) bicyclo [2.2.2] octane-2-carboxylic acid; method to prepare it; pharmaceutical composition comprising it; and its use in the treatment of influenza; method to reduce influenza virus in vitro.
EP2377551A3 (en) Adjuvanted influenza vaccines including cytokine-inducing agents
NZ596870A (en) Vaccine compositions comprising a saponin adjuvant
JP2011504486A5 (en)
WO2007024941A3 (en) Polyvalent vaccine
TW200643028A (en) Vaccine
AR041880A1 (en) IMMUNOGEN COMPOSITION
JP2009501901A5 (en)
WO2007052059A3 (en) Changing th1/th2 balance in split influenza vaccines with adjuvants
MX2009006178A (en) Salmonella vaccine.
BRPI0312194B8 (en) recombinant mononegavirales virus, recombinant measles virus, recombinant measles virus vector, rescue system, immunogenic composition and vaccine composition
WO2002087494A3 (en) Novel vaccine
BR0010323A (en) Immunogenic compositions, kit and method of making it for use in the immunization of a mammal
WO2014150822A3 (en) Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
SG160328A1 (en) Adjuvant composition comprising aluminium phosphate and 3d-mpl
WO2006067635A3 (en) USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT
MX2007002659A (en) Vaccine composition against hepatitis c virus.
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 06 NOV 2013 BY FB RICE

Effective date: 20130205

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 06 NOV 2016 BY CPA GLOBAL

Effective date: 20131003

ASS Change of ownership

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS LIMITED, GB

Effective date: 20160128

LAPS Patent lapsed